Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients

Summary

The purpose of this study is to assess the response to Taxotere (docetaxel) chemotherapy given as a primary treatment to patients with early and rapid PSA rising after prostatectomy for high risk disease.

Timeline

Start

2008-05

Primary completion

2008-07

Completion

2008-07

Outcome

Outcome not reported

Stopped (Business): “Prematurely terminated due to financial considerations”

Drugs

Indications